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iscussion
r J. Chachques (Paris, France). Number one, I want to ask you
f you evaluated the right ventricular volume dimensions and
unction, because I think you can make more compression in the
ight side than in the left. Number two, what is the evaluation of
he apex in these patients? Do you have some degree of dilatation?
nd finally, do you have some degree of fibrosis in the clinical
xperimental studies which is the ration and material that has made
his device.
Dr. Klodell. Thank you for those questions. Concerning the
ight heart function, we didn’t present that data. The right heart
unction is evaluated by echo. There has not been any significant
hange in right heart function. The right heart pressures were also
onitored perioperatively in the bulk of the patients and implan-
ation of the device did not have any deleterious effects.
As far as the shape of the apex, to which you alluded, many of
hese patients have quite spherical hearts with elevated sphericity
ndices. One of the tricks of deployment is a little bit of apical
raction with that suction cup to try and elongate the apex. thereby
aking the device deploy a little easier.
As to your third question, as far as fibrosis is concerned, we
on’t have any information regarding humans yet, but in the
nimal model at least, the degree of reaction and fibrosis to the
itinol based device has been much less than the other support
evice, and it is hoped that that will translate into humans as well.
Dr S. Gideon (Beer Sheba, Israel). Did you have any bleeding
omplications due to erosion of epicardial blood vessels?
Dr Klodell. No, sir, to date there have been no bleeding
omplications, with the exception of the epicardial laceration from
he introducer that I mentioned. None of the treated patients who
ave had a successful implant have subsequently had any bleeding
omplications.
Dr P. Kurlansky (Miami, Fla). I was wondering if you could
elp us to understand the device a little better. From the graph that
ou showed us, this is an extremely compliant material; therefore,
t doesn’t seem as though there is passive restraint. It would seem
hat in fact this would have a lot of give to it, but it would also be,
s it were, hugging the heart. If you can kind of explain to us a
ittle better the physiology of what is going on or perhaps even the
echanics of what is going on with the device, because it doesn’t
eem to be the same as the other sort of passive restraint device
hat is attempting to be on the market. Thank you. c
The Journal of ThoracicDr Klodell. I think that is a great question: Basically, what are
he differences between this device and the CorCap device? First
f all, this device is implanted completely differently. This is a
inimal access, a 9- to 10-cm thoracotomy incision, and the
ericardium is left intact. This is in contrast to how the other the
evice is implanted via sternotomy. And the sizing of this device,
o which you alluded, is a little different. This device is sized based
n MRI and echo data preoperatively. Currently, there are 12 sizes,
o the device is selected based on the size of the heart you are
oing to put it on. Because nitinol has elasticity that when exposed
o body temperature tends to constrict a little bit, it conforms very
icely to the heart. As opposed to the other device, which is a
assive device that only prevents dilation, this actually has some
lasticity to it; although it is very compliant, it also has elasticity
o it. So there is a constant pressure on the ventricle that is
robably along the order of 4 mm or so of magnitude, and what
hat is going to do long term is unclear at this time. I will share
ith you that the Magdeberg Germany group has submitted an
bstract to the Heart Failure Society in which, hopefully, we will
e hearing then that the elasticity feature may contribute to cardiac
esynchronization.
Dr J. Puskas (Atlanta, Ga). Dr. Klodell, you had 2 out of 10
n this original series die of device related deaths and 1 of 10
borted due to epicardial tear. Tell us about evaluation preopera-
ively for epicardial and pericardial adhesions. How can we avoid
he difficulties inserting these?
Dr Klodell. Very good question. Thank you. Just to be clear, it
as 1 epicardial laceration out of 21 patients and 2 patients out of
he 21 that we presented today.
The preoperative evaluation, the things that we have learned
rom the U.S. patients so far is that patients who have an ischemic
tiology frequently will have some pericardial adhesions. That can
e problematic, certainly. Any patients who have epicardial LV
eads and things like that should be excluded. We didn’t have time
o cover in too much detail the operative approach, but one thing
hat has been very useful is when the introducer is inserted into the
ericardial space to use a thoracoscope through the introducer to
ook at the heart and to try and make sure there are not adhesions
here. When there are adhesions, at least in the European experi-
nce and in our experience in a couple of patients, those adhesions
an be taken down under direct vision using the thoracoscope. But
do think that as far as the one patient that was aborted is
oncerned, preoperative nutrition status and overall qualitative
ssessment of the patient probably would have deterred that im-
lant, and that is something to learn for the future: these need to be
he same kind of relatively healthy patients who you would feel
omfortable putting on bypass for a cardiac operation.
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